HIV-associated dementia

Miguel G. Madariaga, Susan Swindells

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

This chapter reviews the use of antiretroviral therapy (ART) including its impact in altering the natural course of human immunodeficiency virus (HIV) disease; an overview of current regimens in use; factors influencing the choice of initial therapy; complications and adverse effects; and treatment failure, and resistance. The focus is on management of primary HIV-related diseases of the nervous system. While there is no specific therapy for HIV-associated dementia (HAD), both approved and developmental antiretroviral agents are discussed with a view to their effect on central nervous system (CNS) viral infection. Adverse drug effects that impact the nervous system are specifically discussed, as are pharmacological interactions between antiretroviral agents and other medications. The significance of cerebrospinal fluid (CSF) penetration by antiretroviral agents is reviewed. Adjunctive therapies, adherence to ART, treatment of comorbidities and coinfections that may worsen neurologic conditions are reviewed and include psychiatric illnesses and substance abuse. Lastly, non-pharmacological treatment strategies, education of patients and caregivers, graded assistance, behavior modification, and environment modifications are covered.

Original languageEnglish (US)
Title of host publicationNeuroimmune Pharmacology
PublisherSpringer US
Pages605-619
Number of pages15
ISBN (Print)9780387725727
DOIs
StatePublished - Dec 1 2008

Fingerprint

Dementia
HIV
Anti-Retroviral Agents
Nervous System
Virus Diseases
Therapeutics
Central Nervous System Viral Diseases
Behavior Therapy
Patient Education
Treatment Failure
Coinfection
Caregivers
Substance-Related Disorders
Psychiatry
Cerebrospinal Fluid
Comorbidity
Pharmacology
Pharmaceutical Preparations

Keywords

  • HIV infection
  • adjuvant therapy
  • antiretroviral therapy
  • dementia

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Madariaga, M. G., & Swindells, S. (2008). HIV-associated dementia. In Neuroimmune Pharmacology (pp. 605-619). Springer US. https://doi.org/10.1007/978-0-387-72573-4_41

HIV-associated dementia. / Madariaga, Miguel G.; Swindells, Susan.

Neuroimmune Pharmacology. Springer US, 2008. p. 605-619.

Research output: Chapter in Book/Report/Conference proceedingChapter

Madariaga, MG & Swindells, S 2008, HIV-associated dementia. in Neuroimmune Pharmacology. Springer US, pp. 605-619. https://doi.org/10.1007/978-0-387-72573-4_41
Madariaga MG, Swindells S. HIV-associated dementia. In Neuroimmune Pharmacology. Springer US. 2008. p. 605-619 https://doi.org/10.1007/978-0-387-72573-4_41
Madariaga, Miguel G. ; Swindells, Susan. / HIV-associated dementia. Neuroimmune Pharmacology. Springer US, 2008. pp. 605-619
@inbook{0d1046a28bc144638992d1ae6f787e1b,
title = "HIV-associated dementia",
abstract = "This chapter reviews the use of antiretroviral therapy (ART) including its impact in altering the natural course of human immunodeficiency virus (HIV) disease; an overview of current regimens in use; factors influencing the choice of initial therapy; complications and adverse effects; and treatment failure, and resistance. The focus is on management of primary HIV-related diseases of the nervous system. While there is no specific therapy for HIV-associated dementia (HAD), both approved and developmental antiretroviral agents are discussed with a view to their effect on central nervous system (CNS) viral infection. Adverse drug effects that impact the nervous system are specifically discussed, as are pharmacological interactions between antiretroviral agents and other medications. The significance of cerebrospinal fluid (CSF) penetration by antiretroviral agents is reviewed. Adjunctive therapies, adherence to ART, treatment of comorbidities and coinfections that may worsen neurologic conditions are reviewed and include psychiatric illnesses and substance abuse. Lastly, non-pharmacological treatment strategies, education of patients and caregivers, graded assistance, behavior modification, and environment modifications are covered.",
keywords = "HIV infection, adjuvant therapy, antiretroviral therapy, dementia",
author = "Madariaga, {Miguel G.} and Susan Swindells",
year = "2008",
month = "12",
day = "1",
doi = "10.1007/978-0-387-72573-4_41",
language = "English (US)",
isbn = "9780387725727",
pages = "605--619",
booktitle = "Neuroimmune Pharmacology",
publisher = "Springer US",

}

TY - CHAP

T1 - HIV-associated dementia

AU - Madariaga, Miguel G.

AU - Swindells, Susan

PY - 2008/12/1

Y1 - 2008/12/1

N2 - This chapter reviews the use of antiretroviral therapy (ART) including its impact in altering the natural course of human immunodeficiency virus (HIV) disease; an overview of current regimens in use; factors influencing the choice of initial therapy; complications and adverse effects; and treatment failure, and resistance. The focus is on management of primary HIV-related diseases of the nervous system. While there is no specific therapy for HIV-associated dementia (HAD), both approved and developmental antiretroviral agents are discussed with a view to their effect on central nervous system (CNS) viral infection. Adverse drug effects that impact the nervous system are specifically discussed, as are pharmacological interactions between antiretroviral agents and other medications. The significance of cerebrospinal fluid (CSF) penetration by antiretroviral agents is reviewed. Adjunctive therapies, adherence to ART, treatment of comorbidities and coinfections that may worsen neurologic conditions are reviewed and include psychiatric illnesses and substance abuse. Lastly, non-pharmacological treatment strategies, education of patients and caregivers, graded assistance, behavior modification, and environment modifications are covered.

AB - This chapter reviews the use of antiretroviral therapy (ART) including its impact in altering the natural course of human immunodeficiency virus (HIV) disease; an overview of current regimens in use; factors influencing the choice of initial therapy; complications and adverse effects; and treatment failure, and resistance. The focus is on management of primary HIV-related diseases of the nervous system. While there is no specific therapy for HIV-associated dementia (HAD), both approved and developmental antiretroviral agents are discussed with a view to their effect on central nervous system (CNS) viral infection. Adverse drug effects that impact the nervous system are specifically discussed, as are pharmacological interactions between antiretroviral agents and other medications. The significance of cerebrospinal fluid (CSF) penetration by antiretroviral agents is reviewed. Adjunctive therapies, adherence to ART, treatment of comorbidities and coinfections that may worsen neurologic conditions are reviewed and include psychiatric illnesses and substance abuse. Lastly, non-pharmacological treatment strategies, education of patients and caregivers, graded assistance, behavior modification, and environment modifications are covered.

KW - HIV infection

KW - adjuvant therapy

KW - antiretroviral therapy

KW - dementia

UR - http://www.scopus.com/inward/record.url?scp=84866511352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866511352&partnerID=8YFLogxK

U2 - 10.1007/978-0-387-72573-4_41

DO - 10.1007/978-0-387-72573-4_41

M3 - Chapter

SN - 9780387725727

SP - 605

EP - 619

BT - Neuroimmune Pharmacology

PB - Springer US

ER -